- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04122885
Study of Plasma Tumor-promoting Factors and Immune Function After Laparotomy, Cytoreductive Surgery and HIPEC vs. PIPAC in Patients With Peritoneal Metastasis (IMMUNOPAC)
Study of Plasma Tumor-promoting Factors and Immune Function After Explorative Laparotomy, Tumor Debulking and HIPEC (Hyperthermic Intraperitoneal Chemotherapy) vs. PIPAC (Pressurized IntraPeritoneal Aerosol Chemothereapy) in Patients With Peritoneal Metastasis as Evaluated by Serum Proliferative Activity, Levels of Proteins, Cytokines, Circulating Growth Factors, Inhibitors and Their Binding Proteins.
The general goal of this study is to investigate the effect of treatment on serum concentrations of proteins known to impact angiogenesis or tumor growth and establishment in patients with peritoneal metastasis of various origin. Since the immune system is thought, by many, to have an impact on tumor growth and development, this study also seeks to determine the impact of abdominal surgery on postoperative immune function in PM patients, as judged by proteins known to influence immune function. This study will not only characterize the postoperative plasma but also to determine if the magnitude of any of the changes noted is associated with a worse or improved oncologic outcome.
The principle purpose of this study is to gather perioperative serum/plasma samples from patients with PM from a variety of different primary tumors (ovarian, gastric, and colorectal) undergoing either CRS and HIPEC versus PIPAC.
Study Overview
Status
Conditions
Detailed Description
The plasma samples obtained in this protocol will also be used to study the various plasma proteins that influence immune function as well as those that influence angiogenesis. In addition to the proteins mentioned above, there are also a large number of other proteins that have not been investigated thus far in the perioperative window; these proteins also merit assessment. The plasma obtained via this study and protocol will also be used to search for other tumor growth factors influenced by surgery or to investigate the impact of surgery on immune function.
Aim 1: To determine perioperative serum levels, over time, of a variety of serum proteins including but not limited to IGFBP-3, VEGF, Ang 2, PlGF, sVCAM, CHI3L1, MMP-2, MMP-3, MCP-1 and proteins that influence immune function as well as other proteins in the following 2 groups of patients:
- PM patients treated with CRS and HIPEC
- PM patients treated with PIPAC.
Aim 2: To compare the perioperative blood protein results between the 2 different groups of patients.
Aim 3: To determine, within each group, a possible correlation between the magnitude of these effects on oncological outcome (patient overall survival).
Aim 4: To search for other surgery-influenced plasma or cellular factors that may influence early postoperative tumor growth or that hold promise as tumor or prognostic markers.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Marc A Reymond, MD MBA
- Phone Number: +4970712986722
- Email: marc.reymond@med.uni-tuebingen.de
Study Contact Backup
- Name: Philipp Horvath, MD
- Phone Number: +4970712986620
- Email: philipp.horvath@med.uni-tuebingen.de
Study Locations
-
-
-
Tübingen, Germany, 72076
- Recruiting
- University Hospital Tübingen
-
Contact:
- Verena Schlaich
- Phone Number: +4970712986722
- Email: verena.schlaich@med.uni-tuebingen.de
-
Sub-Investigator:
- Rami Archid, MD
-
Sub-Investigator:
- Philipp Horvath, MD
-
Sub-Investigator:
- Giorgi Nadiradze, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Subjects will be recruited from the institutions involved. All patients must meet inclusion/exclusion criteria (as indicated above) to be considered.
Each subject will undergo medical examination during the screening visit (Visit 1) prior to enrolment. The personal data and detailed medical history will be recorded. The screening will take place no more than 6 weeks before intervention. This screening procedure will consist of:
- Checking of inclusion/exclusion criteria
- Detailed history including medical history
- A standard physical examination including the cardiovascular, nervous, respiratory systems, conscience, memory, orientation, and body weight
The patient's informed consent for study participation will be signed at the time of enrollment.
Description
Inclusion Criteria:
Adult patients (18 years of age or older) with ovarian, gastric, or colorectal cancer who have PM who after thorough evaluation are deemed candidates for:
- CRS & HIPEC if complete cytoreductive surgery is possible (OR)
- PIPAC if no complete cytoreductive surgery is possible at the University Hospital of Tubingen are eligible for entry in this study
Exclusion Criteria:
- ASA 3 & 4 patients
- Patients who have received chemotherapy within 1 month prior to the planned surgery
- Patients who have received blood transfusion(s) within 2 weeks of the planned surgery
- Patients in whom the treatment plan includes systemic chemotherapy to be given during the first 2 weeks after surgery.
- History of allergic reaction to cisplatin or other platinum containing compounds or doxorubicin
- Severe renal impairment, myelosuppression, severe hepatic impairment, severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias
- Immunocompromised patients such as those taking an immunosuppressive medication and those who have a known disease of the immune system
- Patients or family members involved in the planning and conduct of the study (applies to University of Tübingen staff involved)
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CRS and HIPEC
Cyroreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
|
If complete cytoreduction possible (CC-0).
Application time 60 min, T 41-43 °C
Other Names:
|
PIPAC
Pressurized IntraPeritoneal Aerosol Chemotherapy (if CRS and HIPEC not possible)
|
Oxaliplatin 92 mg/m2 BSA, applied as an aerosol for 30 min under normothermic conditions at 12-15 mmHg pressure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum levels of the proteins of interest over time
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postoperative complications
Time Frame: 30 days
|
30 days
|
|
Overall survival
Time Frame: 18 months
|
Measured from time point of intervention
|
18 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marc A Reymond, MD MBA, National Center for Pleura and Peritoneum
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 392/2018BO1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peritoneal Cancer
-
University of Michigan Rogel Cancer CenterCompletedOvarian, Fallopian Tube, and Primary Peritoneal CancerUnited States
-
AstraZenecaCompletedOvarian, Fallopian Tube, Peritoneal Cancer, P53 MutationUnited States, Canada, Netherlands
-
K-Group, Beta, Inc., a wholly owned subsidiary...RecruitingHigh-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerUnited States, Australia, France
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnOvarian, Fallopian Tube and Peritoneal CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Gateway for Cancer ResearchActive, not recruitingPrimary Peritoneal Cancer | Fallopian Tube | Epithelial OvarianUnited States
-
Eli Lilly and CompanyCompletedOvarian Cancer | Primary Peritoneal CancerGermany, Argentina, Canada, Poland, Sweden
-
Yonsei UniversityCanariaBio Inc.RecruitingPARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum RetreatmentKorea, Republic of
-
Peking UniversityRecruitingPrimary Peritoneal Cancer | Refractory Metastatic Digestive System CarcinomaChina
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditions
-
University of California, San DiegoCompleted
Clinical Trials on Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy
-
CHU de ReimsCompleted
-
Hospices Civils de LyonCompletedOvarian Cancer | Peritoneal CarcinomaFrance
-
Hospices Civils de LyonCompletedGastric Cancer | Peritoneal CarcinomatosisFrance
-
Affiliated Cancer Hospital & Institute of Guangzhou...Chongqing University Cancer Hospital; Xiangya Hospital of Central South University and other collaboratorsRecruitingFallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal CarcinomaChina
-
The Netherlands Cancer InstituteUniversity Medical Center Groningen; UMC Utrecht; Erasmus Medical Center; Catharina...RecruitingPeritoneal Carcinomatosis | Stomach NeoplasmNetherlands
-
Kyungpook National University HospitalNot yet recruitingColorectal Cancer MetastaticKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterMayo Clinic; University of Chicago; University of Pittsburgh; Baptist Health South... and other collaboratorsActive, not recruitingOvarian Cancer | Peritoneal Cancer | Fallopian Tubes CancerUnited States
-
University of RegensburgHeinrich-Heine University, DuesseldorfTerminatedColorectal Cancer Metastatic | Peritoneal CarcinomatosisGermany
-
Guangdong Provincial Hospital of Traditional Chinese...UnknownStage IV Gastric Cancer With Metastasis | Hyperthermic Intraperitoneal Chemotherapy | Exploratory BehaviorChina
-
Tata Memorial CentreRecruitingColorectal Cancer | Ovarian Cancer | Peritoneal DiseaseIndia